Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms BMS-986349, CC 93269, CC-93269 + [1] |
Target |
Action inhibitors, agonists |
Mechanism BCMA inhibitors(B-cell maturation protein inhibitors), CD3ε agonists(CD3e molecule agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Multiple Myeloma | Phase 3 | China | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Japan | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Argentina | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Australia | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Austria | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Belgium | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Brazil | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Canada | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Chile | 03 May 2024 | |
Multiple Myeloma | Phase 3 | Czechia | 03 May 2024 |
Phase 3 | 466 | ezkccytzhg(flelnjpsek) = jtddpokojb pvrwvkkdxj (aiknqktuvh ) View more | Positive | 14 May 2024 | |||
Phase 1 | 73 | xupjqcockp(hnivvxnuwi) = hfklpdrfcd elhjsxcmdn (auqyktdhqq ) View more | - | 09 Dec 2023 | |||
Not Applicable | 1,926 | BCMA-directed BsAbs | enualimokt(xvgegmgxls) = peayoqirzx lnllalqbrs (hzlprwuqqf ) View more | - | 09 Dec 2023 | ||
Phase 1 | 70 | rsgjaadrue(ifpromrvbs) = Any-G/G3-4 treatment-emergent adverse events (TEAEs) occurred in 99%/79% of SC pts; most common were CRS (56%/0%), neutropenia (49%/42%), infections (47%/10%), anemia (41%/25%), and thrombocytopenia (33%/14%) qthuydgvle (yctddwjzqz ) View more | - | 08 Jun 2023 | |||
Phase 1 | - | IV ALNUC | vhkeihpbos(kicamuarrp) = cgimiarcky ftyihlnghu (fosqxwpjpt ) | - | 08 Jun 2023 | ||
Phase 1 | 70 | ohjlxgplss(swporhacit) = rbfsgvxwqg kfayhzznwk (uhnsjqqafa ) View more | Positive | 15 Nov 2022 | |||
Phase 1 | 30 | kspoougcjb(vuzwgvnzhf) = CRS was reported in 23 (77%) pts, the majority of whom reported a maximum grade 1 (n=15 [50%]) or grade 2 (n=7 [23%]), and occurred most frequently with the first or second dose (n=30 of 37 events [81%]) lbnhxwvuae (zwrsnauxsy ) View more | Positive | 14 May 2020 |